WavoDyne Logo

PUBLICATIONS BY OUR INDUSTRY EXPERTS

Special Events

We’ll be presenting on March 11th at the 23rd Annual “Future Leaders in the Biotech Industry” in NYC; A Collaborative Gathering for the Corporate & Investment Communities Featuring Rising Private Plays and Momentum-Building Public Companies.

We’ll also attending and Partnering at the Resi Conference at the Texas Medical Center Accelerator in Houston on Monday, April 11th.

Press Releases

Scientific Publications

Dr. Harris Gelbard

Selected Related Publications

    2016
  • Dong, W., Embury, C.M., Lu, Y., Whitmire, S.M., Dyavarshetty, B., Gelbard, H.A., Gendleman, H.E., Kiyota, T. The Mixed Lineage Kinase 3 inhibitor URMC-099 Facilitates Microglial Amyloid-β Degradation. J. Neuroinflammation 2016, 13,184. DOI 10.1186/s 12974-016-0646-Z.
  • Zhang, G, Guo, D, Dash, P, Arainga, M, Wiederin, JL, Haverland, NA, Knibbe-Hollinger, J, Martinez-Skinner, A, Ciborowski, P, Goodfellow, VS, Wysocki, TA, Wyosocki, BJ, Poluektova, LY, Liu, X-M, McMillan, JM, Gorantla, S, Gelbard, HA and Gendelman, HE. The Mixed Lineage Kinase-3 Inhibitor URMC-099 Improves Therapeutic Outcomes for Long-Acting Antiretroviral Therapy. Nanomedicine. 2016 Jan;12(1):109-22. doi: 10.1016/j.nano.2015.09.009. Epub 2015 Oct 22; featured article selected for cover of January 2016 PMID: 26472049.
  • 2015
  • Puccini, JM, Marker, DF, Fitzgerald, T, Barbieri, J, Kim, CS, Miller-Rhodes, P, Lu, S-M, Dewhurst, S and HA Gelbard. LRRK2 Modulates Neuroinflammation and Neurotoxicity in Models of HIV-1 Associated Neurocognitive Disorders. J Neurosci. 2015 Apr 1;35(13):5271-83. doi: 10.1523/JNEUROSCI.0650-14.2015
  • 2014
  • Boska, MD, Dash, PK, Knibbe, J, Epstein, AA, Akhter, SP, Fields, N, High, R, Makarov, E, Bonasera, S, Gelbard, HA, Poluetkova, LY, Gendelman, HE and S Gorantla. Associations between brain microstructures, metabolites and cognitive deficits during chronic HIV-1 infection of humanized mice. Mol. Neurodegen. 2014 Dec 18;9:58. doi: 10.1186/1750-1326-9-58.
  • Gendelman HE, Gelbard HA. Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders. Curr Opin HIV AIDS. 2014 Nov;9(6):585-90. doi: 10.1097/COH.0000000000000111. PMID: 25226025.
  • Polesskaya O, Wong C, Lebron L, Chamberlain JM, Gelbard HA, Goodfellow V, Kim M, Daiss JL, and S Dewhurst. MLK3 regulates fMLP-stimulated neutrophil motility. Mol. Immunol. 2014 58(2):214-22. doi: 10.1016/j.molimm.2013.11.016. Epub 2014 Jan 3. PMID: 24389043.
  • Guo, D, Zhang, G, Wysocki, TA, Wysocki, BJ, Gelbard, HA, Liu, X, McMillan, JE and HE Gendelman. Endosomal Trafficking of Nanoformulated Antiretroviral Therapy Facilitates Drug Particle Carriage and HIV Clearance. J. Virol. 2014 Jun 11. pii: JVI.01557-14. [Epub ahead of print] PMID: 24920821.
  • Rhoo KH, Granger M, Sur J, Feng C, Gelbard HA, Dewhurst S, Polesskaya O. Pharmacologic Inhibition of MLK3 Kinase Activity Blocks the In Vitro Migratory Capacity of Breast Cancer Cells but Has No Effect on Breast Cancer Brain Metastasis in a Mouse Xenograft Model. PLoS One. 2014 Sep 29;9(9):e108487. doi: 10.1371/journal.pone.0108487. eCollection 2014. PMID: 25264786.
  • 2013
  • Tremblay MÈ, Marker DF, Puccini JM, Muly EC, Lu SM, and Gelbard HA. Ultrastructure of microglia-synapse interactions in the HIV-1 Tat-injected murine central nervous system. Commun Integr Biol. 2013 Nov 1;6(6):e27670. doi: 10.4161/cib.27670. Epub 2013 Dec 31. PMID: 24563721.
  • Marker DF, Tremblay M-È, Puccini JM, Barbieri J, Gantz Marker MA, Loweth CJ, Muly EC, Lu S-M, Goodfellow VS, Dewhurst S and Gelbard HA. The new small molecule mixed lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of HIV associated neurocognitive disorders. J. Neurosci. 2013 Jun 12;33(24):9998-10010. PMID: 23761895. SciBX (Nature) still pending.
  • Ma Q, Gelbard HA, Maggirwar SB, Dewhurst S, Gendelman HE, Peterson DR, Difrancesco R, Hochreiter JS, Morse GD, Schifitto G. Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. J Neurovirol. 2013 Jun;19(3):254-60. doi: 10.1007/s13365-013-0172-z. Epub 2013 Jun 5. PMID: 23737347
  • Goodfellow V, Loweth C, Ravula S, Wiemann T, Nguyen T, Xu Y, Todd D, Sheppard D, Pollack S, Polesskaya O, Marker D, Dewhurst S, and Gelbard HA. Discovery, Synthesis and Characterization of an Orally Bioavailable, Brain Penetrant Inhibitor of Mixed Lineage Kinase 3. J. Med. Chem., 2013 Oct 24;56(20):8032-48. doi: 10.1021/jm401094t. Epub 2013 Oct 3. PMID: 24044867.
  • 2012
  • Marker DF, Tremblay M-È, Puccini JM, Barbieri J, Gantz Marker MA, Loweth CJ, Muly EC, Lu S-M, Goodfellow VS, Dewhurst S and Gelbard HA. The new small molecule mixed lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of HIV associated neurocognitive disorders. J. Neurosci. 2013 Jun 12;33(24):9998-10010. PMID: 23761895.
  • Dash PK, Gendelman HE, Roy U, Balkundi S, Alnouti Y, Mosley RL, Gelbard HA, McMillan J, Gorantla S, Poluektova LY. Long-acting NanoART Elicits Potent antiretroviral and neuroprotective responses in HIV-1 Infected Humanized Mice. AIDS. 2012 Nov 13;26(17):2135-44. doi: 10.1097/QAD.0b013e328357f5ad. PMID: 22824628
  • 2011
  • Lu, SM, Tremblay, MÈ, King, IL, Qi, J, Reynolds, HM, Marker, DF, Varrone, JJ, Majewska, AK, Dewhurst, S, and Gelbard, HA. HIV-1 Tat-Induced Microgliosis and Synaptic Damage via Interactions between Peripheral and Central Myeloid Cells. PLoS One. 2011;6(9):e23915. Epub 2011 Sep 2. (Faculty of 1000, Rating 10/10) PMID: 21912650.
  • Perry, S W, Norman, JP, Barbieri, J, Brown, EB and HA Gelbard. Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. Biotechniques. (February 2011) 50:98-115 (most frequently viewed article of 2011). PMID: 21486251.
  • 2010
  • Gelbard HA, Dewhurst S, Maggirwar SB, Kiebala M, Polesskaya O, Gendelman HE. Rebuilding synaptic architecture in HIV-1 associated neurocognitive disease: a therapeutic strategy based on modulation of mixed lineage kinase. Therapeutics. 2010 Oct;7(4):392-8. PMID: 20880503

Recent Publications Relevant to WavoDyne R&D Activities

2016

  • Li, W., Tong, H-I., Gorantla, S., Polucktova, L., Gendelman, H.E. Neuropharmacologic Approaches to Restore the Brain’s Microenvironment. J. Neuroimmune Pharmacol., published online 28, June, 2016. PMID: 27401058. DOI 10.1007/s11481-016-9686-5.
  • Ibrahim, S.H., Hirsova, P., Tomita, K., Bronk, S.F., Werneburg, N.W., Harrison, S.A., Goodfellow, V.S., Malhi,H., Gores, G.J. Mixed Lineage Kinase 3 Mediates Release of C-X-C Motif Ligand 10-bearing Chemotactic Extracellular Vesicles from Lipotoxic Hepatocytes. Hepatology 2016. 63 (3), 731. DOI 10.1002/hep.2852
  • Sowa, J.-P., Fingas, C.D., Canbay, A.. Mixed Lineage Kinase 3 Connects Hepatocellular Lipotoxicity with Macrophage Chemotaxis. Hepatology 2016 63 (3), 685. DOI 10.1002/hep.28333.

Research Funding

Total Federal Research Funding (anticipated):
Principal Investigator: $38.4 mm

Total Federal Research Funding Received-to-date:
Principal Investigator: $29.8 mm


  View Full Funding Details